Understanding the controversy about hormonal replacement therapy: Insights from estrogen effects on experimental and clinical atherosclerosis

Archives des Maladies du Coeur et des Vaisseaux

Volumn 100, Issue 6-7, 2007, Pages 554-562

  Arnal, Jean François ^b   Douin Echinard, V ^b   Tremollieres F ^b   Terrisse, A D ^b   Sie P ^b   Payrastre, B ^a   Guery, J C ^a   Bayard, F ^b   Gourdy, P ^b  

^a CHU PURPAN   (France)

^b CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MEDROXYPROGESTERONE ACETATE; NANDROLONE; NITRIC OXIDE; PROGESTERONE; PROSTACYCLIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADAPTIVE IMMUNITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FATTY STREAK; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; POSTMENOPAUSE; PREMENOPAUSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CORONARY ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MICE; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 34547786780     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama 1998, 280: 605-13.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama 2002, 288: 321-33.
3. Hodgin J, Maeda N. Estrogen and mouse models of atherosclerosis. Endocrinology 2002, 143: 4495-4501.
4. Waters DD, Gordon D, Rossouw JE, et al. Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 4: lessons from hormone replacement trials. Circulation 2004, 109: e53-55.
5. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002, 8: 1211-17.
6. Gimbrone MA, Jr. Vascular endothelium, hemodynamic forces, and atherogenesis. Am J Pathol 1999, 155: 1-5.
7. Shyy JY, Chien S. Role of integrins in endothelial mechanosensing of shear stress. Circ Res 2002, 91: 769-75.
8. Tricot O, Mallat Z, Heymes C, et al. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation 2000, 101: 2450-53.
9. Ross R. Atherosclerosis - an inflammatory disease. New England Journal Of Medicine 1999, 340: 115-25.
10. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86: 515-81.
11. Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002, 91: 281-91.
12. Libby P. Inflammation in atherosclerosis. Nature 2002, 420: 868-74.
13. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258: 468-71.
14. Smith JD, Trogan E, Ginsberg M, et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proceedings of the National Academy of Sciences of the United States of America 1995, 92: 8264-68.
15. Dansky H, Charlton S, McGee Harper M, Smith J. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1997, 94: 4642-46.
16. Binder CJ, Chang MK, Shaw PX, Miller YI, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002, 8: 1218-26.
17. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002, 196: 887-96.
18. Clarkson TB, Appt SE. Controversies about HRT - lessons from monkey models. Maturitas 2005, 51: 64-74.
19. Arnal JF, Gourdy P, Elhage R, et al. Estrogens and atherosclerosis. Eur J Endocrinol 2004, 150: 113-17.
20. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005, 308: 1583-87.
21. Bourassa PA, Milos PM, Gaynor BJ, et al. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1996, 93: 10022-27.
22. Elhage R, Arnal JF, Pierragi M-T, et al. Estradiol-17b prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscl Thromb Vasc Biol 1997, 17: 2679-2684.
23. Haarbo J, Leth-Espensen P, Stender S, et al. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 1991, 87: 1274-79.
24. Holm P, Andersen HL, Andersen MR, et al. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. Circulation 1999, 100: 1727-33.
25. Elhage R, Clamens S, Reardon-Alulis C, et al. Loss of atheroprotective effect of estradiol in immunodeficient mice. Endocrinology 2000, 141: 462-65.
26. Elhage R, Gourdy P, Brouchet L, et al. Deleting TCR alpha beta + or CD4 + T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice. Am J Pathol 2004, 165: 2013-18.
27. Elhage R, Gourdy P, Huc X, et al. The Atheroprotective Effect of 17 -Estradiol Depends on Complex Interactions in Adaptive Immunity. Am J Pathol 2005, 167: 267-74.
28. Ghisletti S, Meda C, Maggi A, Vegeto E. 17 {beta}-Estradiol Inhibits Inflammatory Gene Expression by Controlling NF-{kappa} B Intracellular Localization. Mol Cell Biol 2005, 25: 2957-68.
29. Deshpande R, Khalili H, Pergolizzi RG, et al. Estradiol down-regulates LPS-induced cytokine production and NFkB activation in murine macrophages. Am J Reprod Immunol 1997, 38: 46-54.
30. Vegeto E, Belcredito S, Etteri S, et al. Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci U S A 2003, 100: 9614-19.
31. Vegeto E, Bonincontro C, Pollio G, Sala A, et al. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci 2001, 21: 1809-18.
32. Soucy G, Boivin G, Labrie F, Rivest S. Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J Immunol 2005, 174: 6391-98.
33. Maret A, Coudert JD, Garidou L, Foucras G, et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur J Immunol 2003, 33: 512-21.
34. Gourdy P, Araujo LM, Zhu R, Garmy-Susini B, et al. Relevance of sexual dimorphism to regulatory T cells: estradiol promotes IFN- {gamma} production by invariant natural killer T cells. Blood 2005, 105: 2415-20.
35. Delpy L, Douin-Echinard V, Garidou L, Bruand C, Saoudi A, Guery JC. Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. J Immunol 2005, 175: 5050-57.
36. Paharkova-Vatchkova V, Maldonado R, Kovats S. Estrogen preferentially promotes the differentiation of CD11c + CD11b (intermediate) dendritic cells from bone marrow precursors. J Immunol 2004, 172: 1426-36.
37. Mendelsohn ME. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean? Circ Res 2000, 87: 956-60.
38. Arnal JF, Clamens S, Pechet C, Nègre-Salvayre A, Allera C, Girolami JP, Solvayre R, Bayard F. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine aortic endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci U S A 1996, 93: 4108-13.
39. Wagner AH, Schroeter MR, Hecker M. 17beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells. Faseb J 2001, 15: 2121-30.
40. Elhage R, Bayard F, Richard V, et al. Prevention of fatty streak formation of 17beta-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice. Circulation 1997, 96: 3048-52.
41. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004, 306: 1954-57.
42. Nagata Y, Yoshikawa J, Hashimoto A, Yamamoto M, Payne AH, Todokoro K. Proplatelet formation of megakaryocytes is triggered by autocrine-synthesized estradiol. Genes Dev 2003, 17: 2864-69.
43. Moro L, Reineri S, Piranda D, Pietrapiana D, et al. Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood 2005, 105: 115-21.
44. Manson JE, Hsia J, Johnson KC, Rossouw JE, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349: 523-34.
45. Anderson GL, Limacher M, Assaf AR, Bassford T, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. Jama 2004, 291: 1701-12.
46. Koh KK, Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler Thromb Vasc Biol 2004, 24: 1171-79.
47. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997, 3: 324-27.
48. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999, 20: 358-17.
49. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 1989, 59: 477-87.
50. Reid G, Denger S, Kos M, Gannon F. Human estrogen receptor-alpha: regulation by synthesis, modification and degradation. Cell Mol Life Sci 2002, 59: 821-31.
51. Lubahn DB, Moyer JS, Golding TS, Couse JF, et al. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 1993, 90: 11162-66.
52. Couse JF, Curtis SW, Washburn TF, Lindzey J, Golding TS, Lubahn DB, Smithies O, Korach KS. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption ofthe estrogen receptor gene. Mol Endocrinol 1995, 9: 1441-1454.
53. Pendaries C, Darblade B, Rochaix P, et al. The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci U S A 2002, 99: 2205-10.
54. Kos M, Denger S, Reid G, et al. Down but not out? A novel protein isoform of the estrogen receptor alpha is expressed in the estrogen receptor alpha knockout mouse. J Mol Endocrinol 2002, 29: 281-86.
55. Flouriot G, Brand H, Denger S, Metivier R, et al. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. Embo J 2000, 19: 4688-700.
56. Metivier R, Penot G, Carmouche RP, Hubner MR, Reid G, Denger S, Manu D, Brand H, Kos M, Benes V, Gannon F. Transcriptional complexes engaged by apo-estrogen receptor-alpha isororms have divergent outcomes. Embo J 2004, 23: 3653-66.
57. Faye JC, Fargin A, Bayard F. Dissimilarities between the uterine estrogen receptor in cytosol of castrated and estradiol-treated rats. Endocrinology 1986, 118: 2276-83.
58. Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A 2003, 100: 4807-12.
59. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 2000, 127: 4277-91.
60. Darblade B, Pendaries C, Krust A, et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res 2002, 90: 413-19.
61. Hodgin JB, Krege JH, Reddick RL, et al. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest 2001, 107: 333-40.
62. Bennett MR, O'Sullivan M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther 2001, 91: 149-66.
63. Carmeliet P, Moos L, Stassen J. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol 1997, 150: 761-76.
64. Brouchet L, Krust A, Dupont S, et al. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 2001, 103: 423-28.
65. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res 1993, 73: 792-96.
66. Iwakura A, Luedemann C, Shastry S, Hanley A, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 2003, 108: 3115-21.
67. Iafrati MD, Karas RH, Aronovitz M, Kim S, et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 1997, 3: 545-48.
68. Pare G, Krust A, Karas RH, et al. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 2002, 90: 1087-92.
69. Strehlow K, Werner N, Berweiler J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003, 107: 3059-65.
70. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 2004, 304: 1269-73.
71. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003, 362: 428-32.
72. Yilmazer M, Fenkci V, Fenkci S, et al. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. Maturitas 2003, 46: 245-53.
73. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG. Effects of estrogen plus progestin on health-related quality of life. N Enql J Med 2003, 348: 1839-1854.
74. Grady D. Postmenopausal hormones - therapy for symptoms only. N Engl J Med 2003, 348: 1835-37.
75. Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R, Merriam GR, Miller VM, Naftolin F, Santoro N. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006, 13: 139-47.
76. de Lignieres B, de Vathaire F, Fournier S, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002, 5: 332-40.
77. Fournier A, Berrino F, Riboli E. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005, 114: 448-54.
78. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-non-specific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001, 104: 719-30.
79. Haynes MP, Li L, Russell KS, Bender JR. Rapid vascular cell responses to estrogen and membrane receptors. Vascul Pharmacol 2002, 38: 99-108.
80. Warner M, Gustafsson JA. Nongenomic effects of estrogen: why all the uncertainty? Steroids 2006, 71: 91-95.
81. Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 1999, 20: 418-34.
82. Jordan VC. The past, present, and future of selective estrogen receptor modulation. Ann N Y Acad Sci 2001 949: 72-79.
83. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res 2001, 61: 5683-87.
84. Katzenellenbogen BS, Katzenellenbogen JA. Biomedicine. Defining the 'S'in SERMs. Science 2002, 295: 2380-2381.